Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pembrolizumab + lenvatinib + carboplatin + etoposide
- Development stage
- Phase 2
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination therapy is being evaluated in the PELICAN Phase II clinical trial (DP-IC001) led by Imperial College London for the treatment of chemotherapy-naïve patients with advanced high-grade neuroendocrine tumors (HG-NETs). The regimen consists of an induction phase using the PD-1 inhibitor pembrolizumab in combination with carboplatin and etoposide chemotherapy, followed by a maintenance phase of pembrolizumab plus the multi-kinase inhibitor lenvatinib. Pembrolizumab is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands (PD-L1 and PD-L2), thereby enhancing T-cell anti-tumor activity. Lenvatinib targets multiple receptor tyrosine kinases including VEGFR1-3, FGFR1-4, PDGFRα, KIT, and RET. Carboplatin and etoposide are standard cytotoxic agents that induce DNA damage and inhibit topoisomerase II, respectively, to provide synergistic anti-tumor effects.
- Other names
- PELICAN regimen
02
Targets
DNAFGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDCD1 (Programmed cell death protein 1 receptor)PDGFRA (Platelet-derived growth factor receptor alpha)RET (Rearranged during transfection receptor tyrosine kinase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on pembrolizumab + lenvatinib + carboplatin + etoposide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pembrolizumab + lenvatinib + carboplatin + etoposide.